Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07563881 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
A Phase 3 study, sponsored by Rapport Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 333
- Enrollment target
NCT07563881: Recruiting Phase 3 study, sponsored by Rapport Therapeutics.
NCT07563881 is a Phase 3 study that is actively recruiting participants, run by Rapport Therapeutics. The registered enrollment target is 333 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07563881, a Phase 3 study, is actively recruiting participants, sponsored by Rapport Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 333 participants
- Enrollment target
Study Summary
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
Primary Outcome
Median percent change in seizure frequency and ≥ 50% seizure frequency reduction responder rates:
Interventions
- OTHER Placebo
- DRUG RAP-219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2029-09 |
| Phase | Phase 3 |
What NCT07563881 shows while recruiting
NCT07563881 is an interventional study that assigns participants to a tested intervention. The registered 333 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07563881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07563881 about?
NCT07563881 is a clinical study titled "Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1". This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.
What is the current status of trial NCT07563881?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 333 participants. The study started on 2026-06-05. Estimated completion is 2029-09.
What interventions are being tested in trial NCT07563881?
The interventions under investigation include: Placebo (OTHER), RAP-219 (DRUG).
Who is sponsoring clinical trial NCT07563881?
This trial is sponsored by Rapport Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07563881's enrollment target sits among peer trials
333 1061st of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07395687 · 333 participants · Phase 2
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
- NCT05131672 · 334 participants · NA
Cast or Operation for Medial Epicondyle Fracture Treatment in Children
- NCT05131685 · 334 participants · NA
Distal Radius Interventions for Fracture Treatment
- NCT05546931 · 334 participants · NA
Mobile Health Program for Rural Hypertension
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI